Peng Zhang, Yan Zhao, Xin Xia, Song Mei, Yixuan Huang, Yingying Zhu, Shuting Yu, Xingming Chen
{"title":"OLR1基因在头颈部鳞状细胞癌肿瘤相关巨噬细胞中的表达及其与临床预后的关系","authors":"Peng Zhang, Yan Zhao, Xin Xia, Song Mei, Yixuan Huang, Yingying Zhu, Shuting Yu, Xingming Chen","doi":"10.1080/2162402X.2023.2203073","DOIUrl":null,"url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is one of the most heavily immune infiltrated human tumors, having distinct immune subtypes associated with different molecular characteristics and clinical outcomes. The tumor microenvironment (TME) of HNSCC which was dominated by tumor-associated macrophages (TAMs) had a relatively inferior prognosis. High levels of oxidized low-density lipoprotein receptor 1 (<i>OLR1</i>) expression are associated with more aggressive and metastatic characteristics in multiple cancers. However, the link between the <i>OLR1</i> expression and immunosuppression of TME, and the molecular mechanisms which govern intratumoral TAMs behavior are unclear. Here, we performed the transcriptional analysis based on a single-cell RNA-sequencing (scRNA-seq) dataset of HNSCC, and found that the <i>OLR1</i> expression was specifically enriched on the TAMs. Evaluation of protein expression within histologic sections of primary HNSCC patient samples showed a co-expression pattern of <i>OLR1</i> and <i>CD68</i> on macrophages. A total of 498 tumor samples of HNSCC patients from The Cancer Genome Atlas (TCGA) database were also analyzed. Remarkably, <i>OLR1</i> expression was dramatically higher in HNSCC tissues than that in adjacent normal tissues, and the patients with high levels of <i>OLR1</i> expression had significantly unfavorable overall survival (Hazard Ratio = 1.724, log-rank <i>P</i>-value = 0.0066) when compared to patients harboring low expression levels of <i>OLR1</i>. In summary, we reported that the specific expression of <i>OLR1</i> on the TAMs was significantly correlated with poor survival outcomes, revealing that <i>OLR1</i> could serve as a potential prognosis marker and promising target for immunotherapy in HNSCC.</p>","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"12 1","pages":"2203073"},"PeriodicalIF":7.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/c2/KONI_12_2203073.PMC10120517.pdf","citationCount":"0","resultStr":"{\"title\":\"Expression of <i>OLR1</i> gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome.\",\"authors\":\"Peng Zhang, Yan Zhao, Xin Xia, Song Mei, Yixuan Huang, Yingying Zhu, Shuting Yu, Xingming Chen\",\"doi\":\"10.1080/2162402X.2023.2203073\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Head and neck squamous cell carcinoma (HNSCC) is one of the most heavily immune infiltrated human tumors, having distinct immune subtypes associated with different molecular characteristics and clinical outcomes. The tumor microenvironment (TME) of HNSCC which was dominated by tumor-associated macrophages (TAMs) had a relatively inferior prognosis. High levels of oxidized low-density lipoprotein receptor 1 (<i>OLR1</i>) expression are associated with more aggressive and metastatic characteristics in multiple cancers. However, the link between the <i>OLR1</i> expression and immunosuppression of TME, and the molecular mechanisms which govern intratumoral TAMs behavior are unclear. Here, we performed the transcriptional analysis based on a single-cell RNA-sequencing (scRNA-seq) dataset of HNSCC, and found that the <i>OLR1</i> expression was specifically enriched on the TAMs. Evaluation of protein expression within histologic sections of primary HNSCC patient samples showed a co-expression pattern of <i>OLR1</i> and <i>CD68</i> on macrophages. A total of 498 tumor samples of HNSCC patients from The Cancer Genome Atlas (TCGA) database were also analyzed. Remarkably, <i>OLR1</i> expression was dramatically higher in HNSCC tissues than that in adjacent normal tissues, and the patients with high levels of <i>OLR1</i> expression had significantly unfavorable overall survival (Hazard Ratio = 1.724, log-rank <i>P</i>-value = 0.0066) when compared to patients harboring low expression levels of <i>OLR1</i>. In summary, we reported that the specific expression of <i>OLR1</i> on the TAMs was significantly correlated with poor survival outcomes, revealing that <i>OLR1</i> could serve as a potential prognosis marker and promising target for immunotherapy in HNSCC.</p>\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"12 1\",\"pages\":\"2203073\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0a/c2/KONI_12_2203073.PMC10120517.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2023.2203073\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2023.2203073","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome.
Head and neck squamous cell carcinoma (HNSCC) is one of the most heavily immune infiltrated human tumors, having distinct immune subtypes associated with different molecular characteristics and clinical outcomes. The tumor microenvironment (TME) of HNSCC which was dominated by tumor-associated macrophages (TAMs) had a relatively inferior prognosis. High levels of oxidized low-density lipoprotein receptor 1 (OLR1) expression are associated with more aggressive and metastatic characteristics in multiple cancers. However, the link between the OLR1 expression and immunosuppression of TME, and the molecular mechanisms which govern intratumoral TAMs behavior are unclear. Here, we performed the transcriptional analysis based on a single-cell RNA-sequencing (scRNA-seq) dataset of HNSCC, and found that the OLR1 expression was specifically enriched on the TAMs. Evaluation of protein expression within histologic sections of primary HNSCC patient samples showed a co-expression pattern of OLR1 and CD68 on macrophages. A total of 498 tumor samples of HNSCC patients from The Cancer Genome Atlas (TCGA) database were also analyzed. Remarkably, OLR1 expression was dramatically higher in HNSCC tissues than that in adjacent normal tissues, and the patients with high levels of OLR1 expression had significantly unfavorable overall survival (Hazard Ratio = 1.724, log-rank P-value = 0.0066) when compared to patients harboring low expression levels of OLR1. In summary, we reported that the specific expression of OLR1 on the TAMs was significantly correlated with poor survival outcomes, revealing that OLR1 could serve as a potential prognosis marker and promising target for immunotherapy in HNSCC.
期刊介绍:
Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy.
While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.